Langley PC. More Unnecessary Imaginary Worlds – Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis, InovPharm. 2020;11(1): No.2

Langley PC. More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes. InovPharm. 2020;11(1). No. 10

Langley P. Nonsense on Stilts – Part 1: The ICER 2020-2023 value assessment framework for constructing imaginary worlds. InovPharm. 2020;11(1):No. 12

Langley P. More Unnecessary Imaginary Worlds – Part 3: Cystic Fibrosis and the Institute for 3333Clinical and Economic Review’s Draft Evidence Report. InovPharm. 2020;11(1): No. 15

Langley P. More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease. InovPharm. 2020;11(2): No. 4

Langley P. Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement. InovPharm. 2020;11(2):No. 8

Langley P. The National Pharmaceutical Council: Endorsing the construction of imaginary worlds in health technology assessment. Pharmacy. 2020;8(119);doi:10.3390/pharmacy8030119

Langley PC, McKenna SP. Measurement, modeling and QALYs [version 1; peer reviewed] F1000Research. 2020; 9:1048

Langley P. The Great I-QALY Disaster. InovPharm. 2020; 11(3): No 7

Langley P. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). InovPharm. 2020;11(3): No. 17

Langley P . Value Assessment, Real World Evidence, and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines. InovPharm. 2020;11(4):No. 12

Langley P. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims. InovPharm. 2020;11(4):No. 22

Langley P. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience. InovPharm. 2021;12(1):No. 5

Langley P. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims. InovPharm. 2021;12(1): No. 11

Langley P, McKenna S. Fundamental Measurement and Quality Adjusted Life Years. Value Health. 2021;24(3):461[letter]

Langley P. McKenna S. Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure. InovPharm.2021;12(2):No. 6

McKenna S, Heaney A, Langley P. Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce. InovPharm. 2021; 12(2): No. 17

Langley P. Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment. InovPharm. 2021; 12(2): No.20

Langley P. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review. InovPharm. 2021; 12(3): No. 6.

Langley P. Abandoning Eugenics and the QALY. InovPharm. 2021;12(3): No. 20

Langley P. A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis. InovPharm. 2021; 12(3): No. 4

Langley P. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis. Inovpharm.2021; (12)4: No. 10

Langley PC. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22 [version 1; peer review: awaiting peer review] 2022